Real-Time EquityWire is available only to registered users. This is best for professional traders and people who track markets actively.Real-Time EquityWire is available only to registered users. This is best for professional traders and people who track markets actively.
Aurobindo Pharma Ltd. today said it is not expecting any "meaningful launches" in the next 6–12 months from its injectables business arm, Eugia Pharma Specialties Ltd., as it is in the process of normalising its operations after key revenue generator Unit-III received a warning letter from the US Food and Drug Administration in August. In a post-earnings conference call Monday, the company's management said the remedial measures at Eugia’s Unit-III are complete, and the company is ramping up its products gradually.
Share this Story:
